Refining AML Treatment: The Role of Genetics in Response and Resistance Evaluation to New Agents.

Halik, Adriane; Arends, Christopher Maximilian; Bullinger, Lars; Damm, Frederik; Frick, Mareike

Halik, Adriane; Arends, Christopher Maximilian; Bullinger, Lars; Damm, Frederik; Frick, Mareike.

Afiliação

Halik A; Medical Department, Division of Hematology, Oncology, and Cancer Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, 13353 Berlin, Germany.
Arends CM; BIH Charité Junior Clinician Scientist Program, Berlin Institute of Health at Charité, BIH Biomedical Innovation Academy-Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany.
Bullinger L; Medical Department, Division of Hematology, Oncology, and Cancer Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, 13353 Berlin, Germany.
Damm F; BIH Charité Junior Clinician Scientist Program, Berlin Institute of Health at Charité, BIH Biomedical Innovation Academy-Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany.
Frick M; Medical Department, Division of Hematology, Oncology, and Cancer Immunology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, 13353 Berlin, Germany.

Cancers (Basel) ; 14(7)2022 Mar 26.

Article em En | MEDLINE | ID: mdl-35406464

Palavras-chave

AML; CPX-351; FLT3; IDH1/2; gemtuzumabozogamicin; mutations; precision medicine; targeted therapy; venetoclax

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google